Bank of New York Mellon
APRE icon

Bank of New York Mellon’s Aprea Therapeutics APRE Stock Holding History

Bank of New York Mellon’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-832
Closed -$12K – 4553
2022
Q2 		$12K Sell
832
-3
-0.4% -$69 ﹤0.01% 4537
2022
Q1 		$31K Sell
835
-7
-0.8% -$287 ﹤0.01% 4583
2021
Q4 		$48K Hold
842
– – ﹤0.01% 4507
2021
Q3 		$86K Hold
842
– – ﹤0.01% 4357
2021
Q2 		$83K Sell
842
-1,547
-65% -$143K ﹤0.01% 4249
2021
Q1 		$244K Buy
2,389
+872
+57% +$102K ﹤0.01% 3990
2020
Q4 		$149K Buy
1,517
+91
+6% +$43.3K ﹤0.01% 4028
2020
Q3 		$686K Buy
1,426
+102
+8% +$57.1K ﹤0.01% 3329
2020
Q2 		$1.03M Sell
1,324
-574
-30% -$377K ﹤0.01% 3099
2020
Q1 		$1.32M Buy
1,898
+1,070
+129% +$785K ﹤0.01% 2783
2019
Q4 		$760K Buy
+828
New +$456K ﹤0.01% 3370

Other funds holding APRE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon's APRE Position: Q3 2022 in Review

Bank of New York Mellon sold out of Aprea Therapeutics (APRE) in Q3 2022, closing a stake of 832 shares — an estimated $12K sold.

Bank of New York Mellon first reported a position in APRE in Q4 2019 and held it in 11 quarters. The position peaked at $1.32M in Q1 2020. 26 funds tracked by Wall St. Rank hold APRE as of Q3 2022.

  • Bank of New York Mellon reported no remaining Aprea Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 832 Aprea Therapeutics shares in Q3 2022, an estimated $12K.
  • Bank of New York Mellon first reported a position in Aprea Therapeutics in Q4 2019 and held it in 11 quarters.
  • Bank of New York Mellon's Aprea Therapeutics position peaked at $1.32M in Q1 2020.
  • 26 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2022.

Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.